We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Analysis

Executive Summary

Both Novo Nordisk and Sanofi had a bumpy start of the year in Asia and emerging markets. Novo saw insulin sales decline in Japan and Korea, while Sanofi grew only 6.5% in emerging markets, well below the company’s long-term guidance of double-digit growth.